Effects of LY354740, a novel glutamatergic metabotropic agonist, on nonhuman primate hypothalamic–pituitary–adrenal axis and noradrenergic function
Abstract
The search for novel anxiolytics and antidepressants has focused on compounds with the potential to reduce excessive hypothalamic-pituitary-adrenal (HPA) axis activity. L-glutamate, an excitatory neurotransmitter ubiquitously present within the central nervous system, conceivably plays an important role in activating the neural sites involved in stress modulation. Deactivation of the HPA axis by glutamatergic neurotransmission modulation may represent a novel therapeutic approach. Accordingly, the acute intravenous effects of the novel metabotropic (mGlu2/3) agonist LY354740 were tested on bonnet macaques (Macaca radiata) undergoing acute infusions of yohimbine, a noradrenergic stimulant. Dependent measures were the magnitude of the increase of plasma cortisol and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) customarily elicited by yohimbine. Next, the effects of 6 weeks of chronic oral administration of LY354740 on baseline (postcapture) plasma cortisol and MHPG levels in comparison to the identical measure in untreated controls were assessed. Subjects chronically treated with LY354740 received yohimbine infusions which were compared to yohimbine infusions and saline infusions in non-LY354740-treated subjects. Preliminary evidence supports the view that acute LY354740 infusion resulted in a marked diminution of yohimbine-induced stress response, as manifest by a substantial attenuation of cortisol and MHPG response observed in comparison to the saline-treated yohimbine condition. Chronic oral administration of LY354740 led to postcapture baseline cortisol levels which were markedly reduced (approximately 50 percent) in comparison to untreated control subjects; however, there were no significant parallel differences in MHPG levels. Yohimbine infusions elicited an increase in cortisol and MHPG levels in both LY354740-treated and non-LY354740-treated subjects, in comparison to declines in cortisol values observed following vehicle infusions (group X time interaction; P<.0001). Chronic LY354740-treated subjects failed to achieve cortisol levels comparable in range to those of untreated subjects primarily because of their low baseline cortisol levels. In contrast, despite equivalent baselines, yohimbine-induced MHPG values were increased overall in the chronically treated group compared to the saline and yohimbine-alone groups. Thus, LY354740 markedly reduced the acute corticoid and noradrenergic response elicited by yohimbine infusion. Chronic administration of LY354740 appears to present a safe and effective mechanism to markedly down-modulate the HPA axis while retaining noradrenergic responsivity.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In macaques captured from the wild, six-week chronic intravenous administration of a Group II agonist reduced basal cortisol levels by as much as 50% compared to controls.
“In macaques captured from the wild, six-week chronic intravenous administration of a Group II agonist reduced basal cortisol levels by as much as 50% compared to controls (Coplan et al., 2001).”
From Glutamate receptors in domestication and modern human evolution (2020) · cites this paper as Coplan et al., 2001
Cites
PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORS
Conn, P. J., & Pin, J. (1997) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.205 · Cited by 3,083 · see citing works
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985 · see citing works
Molecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543 · see citing works
Psychopharmacology: The Fourth Generation of Progress
Brophy, J. J. (1995) · JAMA · doi:10.1001/jama.1995.03530220079046 · Cited by 1,582 · see citing works
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399 · see citing works
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006 · see citing works
Coplan, J. D., Andrews, M. W., Rosenblum, L. A., Owens, M. J., Friedman, S., Gorman, J. M., & Nemeroff, C. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1619 · Cited by 649 · see citing works
Self-citationPsychobiologic mechanisms of posttraumatic stress disorder.
Charney, D., Deutch, A., Krystal, J., Southwick, S., & Davis, M. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820160064008 · Cited by 610 · see citing works
Helton, D. R., Tizzano, J. P., Monn, J. A., Schoepp, D. D., & Kallman, M. J. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37253-2 · Cited by 279 · see citing works
Self-citationSchoepp, D. D., Johnson, B. G., Wright, R. A., Salhoff, C. R., Mayne, N. G., Wu, S., Cockerham, S. L., Burnett, J. P., BELEGAJE, R., Bleakman, D., et al. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(96)00160-8 · Cited by 225 · see citing works
Self-citationvan den Pol, A. N., Hermans‐Borgmeyer, I., Hofer, M., Ghosh, P. K., & Heinemann, S. (1994) · The Journal of Comparative Neurology · doi:10.1002/cne.903430307 · Cited by 191 · see citing works
Battaglia, G., Monn, J. A., & Schoepp, D. D. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00442-4 · Cited by 163 · see citing works
Self-citationNovel functions for subtypes of metabotropic glutamate receptors
Schoepp, D. D. (1994) · Neurochemistry International · doi:10.1016/0197-0186(94)90092-2 · Cited by 130 · see citing works
Self-citationHelton, D. R., Tizzano, J. P., Monn, J. A., Schoepp, D. D., & Kallman, M. J. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00170-6 · Cited by 103 · see citing works
Self-citationVandergriff, J. L., & Rasmussen, K. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00196-8 · Cited by 94 · see citing works
α2-Adrenergic Receptor Function in Depression
Price, L. H. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800090035006 · Cited by 88 · see citing works
Krystal, J. H., McDougle, C. J., Woods, S. W., Price, L. H., Heninger, G. R., & Charney, D. S. (1992) · Psychopharmacology · doi:10.1007/bf02245117 · Cited by 41 · see citing works
Uncoupling of the Noradrenergic-Hypothalamic-Pituitary-Adrenal Axis in Panic Disorder Patients
Coplan, J. D., Pine, D., Papp, L., Martinez, J., Cooper, T., Rosenblum, L. A., & Gorman, J. M. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00018-9 · Cited by 39 · see citing works
Self-citationMetabotropic Glutamate Receptors and Brain Function
Moroni, F., Nicoletti, F., & Pellegrini-Giampietro, D. E. (1998) · Florence Research (University of Florence) · Cited by 34 · see citing works
Synaptic transmission: Well-placed modulators
Forsythe, I. D., & Barnes‐Davies, M. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00175-8 · Cited by 32 · see citing works
Metabotropic glutamate receptor in vasopressin, CRF and VIP hypothalamic neurones
Kocsis, K., Kiss, J. Z., Görcs, T. J., & Halász, B. (1998) · Neuroreport · doi:10.1097/00001756-199812210-00008 · Cited by 21 · see citing works
Flagged first, then by citations
1 of the 22 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
Pałucha-Poniewiera, A., & Pilc, A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.007 · Cited by 220 · see citing works
New perspectives in glutamate and anxiety
Riaza Bermudo-Soriano, C., Perez-Rodriguez, M. M., Vaquero-Lorenzo, C., & Baca-Garcia, E. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.010 · Cited by 207 · see citing works
LY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress
Schoepp, D. D., Wright, R. A., Levine, L. R., Gaydos, B. L., & Potter, W. Z. (2003) · Stress · doi:10.1080/1025389031000146773 · Cited by 207 · see citing works
Self-citationPotential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010) · CNS Drugs · doi:10.2165/11533230-000000000-00000 · Cited by 180 · see citing works
Self-citationMolecular targets in the treatment of anxiety
KENT, J. M., Mathew, S. J., & Gorman, J. M. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01672-4 · Cited by 167 · see citing works
Self-citationOpen-Label Trial of Riluzole in Generalized Anxiety Disorder
Mathew, S. J., Amiel, J. M., Coplan, J. D., Fitterling, H. A., Sackeïm, H. A., & Gorman, J. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.12.2379 · Cited by 134 · see citing works
Self-citationHarvey, B. H., & Shahid, M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.014 · Cited by 88 · see citing works
Schönenberg, M., Reichwald, U., Domes, G., Badke, A., & Hautzinger, M. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0094-4 · Cited by 81 · see citing works
Advances in the treatment of anxiety: Targeting glutamate
Simon, A. B., & Gorman, J. M. (2006) · NeuroRx · doi:10.1016/j.nurx.2005.12.005 · Cited by 54 · see citing works
Self-citationNew molecular targets for antianxiety interventions.
Gorman, J. M. (2003) · PubMed · Cited by 52 · see citing works
Self-citationGlutamate receptors in domestication and modern human evolution
O’Rourke, T., & Boeckx, C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.10.004 · Cited by 50 · see citing works
Ma, N., Liu, X., Chen, X., Wang, X., Wei, Y., Han, G., Chen, G., Hou, C., Shen, B., Li, Y., et al. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.05.016 · Cited by 20 · see citing works
Developmental expression of mGlu2 and mGlu3 in the mouse brain
McOmish, C. E., Demireva, E. Y., & Gingrich, J. A. (2016) · Gene Expression Patterns · doi:10.1016/j.gep.2016.10.001 · Cited by 19 · see citing works
Taurine prevents MK-801-induced shoal dispersion and altered cortisol responses in zebrafish
Franscescon, F., Souza, T. P., Müller, T. E., Michelotti, P., Canzian, J., Stefanello, F. V., & Rosemberg, D. B. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110399 · Cited by 14 · see citing works
The endocrine system of the non-human primate
Chilton, J. A., Sjögren, I., Mølck, A., & Thorup, I. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-813088-9.00001-x · Cited by 1 · see citing works
Costa, D. L. D. C. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2016.tde-05122016-164417 · Cited by 1 · see citing works
Understanding the causes of anxiety
Simpson, H. B., Neria, Y., Lewis-Fernández, R., & Schneier, F. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777578.015
Non-human primate models in understanding anxiety
Natarajan, N. A., Shrestha, R., & Coplan, J. D. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777578.023
Self-citation
- Authors
- Coplan, J. D., Mathew, S. J., Smith, E. L. P., Trost, R. C., Scharf, B. A., Martinez, J., Gorman, J. M., Monn, J. A., Schoepp, D. D., & Rosenblum, L. A.
- Affiliations
- State University of New York (US)
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2001-07
- Volume
- 6
- Issue
- 7
- Pages
- 607-617
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W191463486
- Cited by
- 18
- References
- 22
- Citations by year
- 2023: 1 · 2021: 1 · 2019: 1 · 2016: 2 · 2015: 1
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Spectrums (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- metabotropic glutamate receptor agonist, mGlu2/3 receptors, hypothalamic-pituitary-adrenal axis, noradrenergic function, yohimbine, plasma cortisol, MHPG, stress response, bonnet macaque, anxiolytics, antidepressants, chronic drug administration, non-human primates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
